---
title: "Olema Pharmaceuticals: Buy Rating Reiterated as Palazestrant Phase 3 Catalysts Loom; $24 Price Target Maintained"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295480242.md"
description: "LifeSci Capital analyst Sam Slutsky reiterated a Buy rating on Olema Pharmaceuticals with a $24 price target. The recommendation is driven by the advancement of palazestrant for ER+ breast cancer and favorable Phase 3 positioning. Key catalysts include upcoming readouts from AstraZeneca’s SERENA-4 and Olema’s OPERA-01 trial by Q1 2027. Despite high burn and short interest, the two-year cash runway limits near-term financing risk, supporting the attractive risk-reward profile."
datetime: "2026-08-11T03:35:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295480242.md)
  - [en](https://longbridge.com/en/news/295480242.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295480242.md)
generator: "portal-rs"
---

# Olema Pharmaceuticals: Buy Rating Reiterated as Palazestrant Phase 3 Catalysts Loom; $24 Price Target Maintained

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Olema Pharmaceuticals today and set a price target of $24.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Sam Slutsky has given his Buy rating due to a combination of factors, including Olema’s continued advancement of palazestrant, its oral SERD/CERAN for ER+ breast cancer, and the favorable positioning of its Phase 3 program against competitors. He views the upcoming readouts from AstraZeneca’s SERENA-4 and Olema’s own OPERA-01 trial by Q1 2027 as key catalysts that could validate palazestrant’s differentiated profile, particularly if robust activity is demonstrated in the ESR1 wild-type population, where prior oral SERDs have struggled.

At the same time, he notes that Olema’s cash runway of roughly two years, despite a relatively high annual burn and notable short interest, appears sufficient to reach these major data events, which limits near-term financing risk while preserving upside to successful trial outcomes. Against this backdrop, Slutsky maintains his $24 price target, unchanged, reflecting a risk-reward he believes remains attractive given the potential commercial opportunity in ER+ breast cancer and the prospect that positive Phase 3 results could materially re-rate the shares.

### Related Stocks

- [OLMA.US](https://longbridge.com/en/quote/OLMA.US.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)

## Related News & Research

- [LifeSci Capital Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)](https://longbridge.com/en/news/286679129.md)
- [LifeSci Capital Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)](https://longbridge.com/en/news/288934562.md)
- [What Are Wall Street Analysts' Target Price for Henry Schein Stock?](https://longbridge.com/en/news/296490175.md)
- [Apimeds Pharmaceuticals US Enters Assignment And Transfer Agreement With Freet On August 19](https://longbridge.com/en/news/296655292.md)
- [39,241 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Bought by GSA Capital Partners LLP](https://longbridge.com/en/news/296452266.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**